[Effects of nuclear factor of kappa B decoy oligodeoxynucleotides on murine with multiple myeloma]
1Department of Blood Purification, Kidney Disease Hospital, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, Shaanxi Province, China.
Objective:
The present study was to evaluate the effects of nuclear factor of kappa B decoy oligodeoxynucleotides on murine multiple myeloma models.
Methods:
The severe combined immunodeficient mice were injected subcutaneously with RPMI-8226 myeloma cells. When tumors became measurable, the mice were divided into 2 treatment groups who respectively received 5 µg/g or 10 µg/g liposome-NF-κB decoy ODN compounds, and one control group was selected; the control group received 10 µg/g liposome-NF-κB mutant decoy ODN compounds, twice per week for 4 weeks. The mice were killed when they died or the tumor diameter became >2 cm.
Results:
The liposome-NF-κB decoy ODN could efficiently suppress NF-κB DNA binding activity and inhibited the expression of IL-6. As compared with the control group, the two liposome-NF-κB decoy ODN-treated groups showed more remarkably survival time and smaller tumor volume.
Conclusion:
In vivo transfection of NF-κB decoy ODN may provide a new therapeutic strategy for multiple myeloma.
Insights
Nuclear factor of kappa B (NF-κB) decoy oligodeoxynucleotides significantly reduced tumor growth and improved survival in multiple myeloma mouse models. This suggests NF-κB decoy ODN is a promising therapeutic strategy for multiple myeloma.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Multiple myeloma is a hematologic malignancy characterized by uncontrolled proliferation of plasma cells.
- Nuclear factor of kappa B (NF-κB) signaling pathway plays a critical role in multiple myeloma cell survival and proliferation.
- Targeting NF-κB offers a potential therapeutic strategy for multiple myeloma.
Purpose of the Study:
- To evaluate the therapeutic efficacy of nuclear factor of kappa B (NF-κB) decoy oligodeoxynucleotides (ODN) in a murine model of multiple myeloma.
- To assess the impact of NF-κB decoy ODN on tumor growth, survival, and NF-κB pathway activity in vivo.
Main Methods:
- Severe combined immunodeficient mice were xenografted with RPMI-8226 myeloma cells.
- Mice with measurable tumors received liposomal NF-κB decoy ODN (5 µg/g or 10 µg/g) or control liposomal mutant decoy ODN twice weekly for 4 weeks.
- Tumor volume, survival rates, and NF-κB DNA binding activity were monitored.
Main Results:
- Liposomal NF-κB decoy ODN effectively suppressed NF-κB DNA binding activity and inhibited interleukin-6 (IL-6) expression.
- Mice treated with NF-κB decoy ODN exhibited significantly prolonged survival times compared to the control group.
- A marked reduction in tumor volume was observed in the NF-κB decoy ODN-treated groups.
Conclusions:
- In vivo delivery of NF-κB decoy ODN demonstrates significant anti-myeloma activity.
- NF-κB decoy ODN represents a potential novel therapeutic strategy for treating multiple myeloma.
- Targeting the NF-κB pathway offers a promising avenue for future multiple myeloma therapies.
More Related Videos
Related Concept Videos
02:43Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
02:26NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...